Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Accured Expenses (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Change in Accured Expenses for 7 consecutive years, with -$670000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Accured Expenses fell 39.58% year-over-year to -$670000.0, compared with a TTM value of $945000.0 through Dec 2019, up 50.48%, and an annual FY2024 reading of $13.4 million, up 1414.68% over the prior year.
  • Change in Accured Expenses was -$670000.0 for Q4 2019 at Larimar Therapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.2 million in Q3 2015 and bottomed at -$1.7 million in Q2 2016.
  • Average Change in Accured Expenses over 5 years is $154300.0, with a median of $260000.0 recorded in 2017.
  • The sharpest move saw Change in Accured Expenses skyrocketed 240.57% in 2017, then crashed 499.24% in 2018.
  • Year by year, Change in Accured Expenses stood at -$407000.0 in 2015, then crashed by 107.13% to -$843000.0 in 2016, then surged by 240.57% to $1.2 million in 2017, then tumbled by 140.51% to -$480000.0 in 2018, then plummeted by 39.58% to -$670000.0 in 2019.
  • Business Quant data shows Change in Accured Expenses for LRMR at -$670000.0 in Q4 2019, $1.6 million in Q3 2019, and $1.1 million in Q2 2019.